Compare
Pacira BioSciences, Inc. vs Supernus Pharmaceuticals, Inc. vs Emergent BioSolutions Inc. vs Corcept Therapeutics Inc
| Latest fiscal year | Pacira BioSciences, Inc. PCRX | Supernus Pharmaceuticals, Inc. SUPN | Emergent BioSolutions Inc. EBS | Corcept Therapeutics Inc CORT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $726.41M | $718.95M | $742.90M | $761.41M |
| Revenue growth (YoY) | +3.6% | +8.6% | -28.8% | +12.8% |
| Gross margin | 79.4% (computed) | 89.6% (computed) | 56.1% (computed) | n/a |
| Operating margin | 2.6% | -8.7% | 13.5% | 5.9% |
| Net margin | 1.0% | -5.4% | 7.1% | 13.1% |
| Net income | $7.03M | -$38.55M | $52.60M | $99.65M |
| EPS (Diluted) | $0.16 | -$0.68 | $0.93 | $0.82 |
| Operating cash flow | $151.99M | $47.33M | $170.60M | $142.00M |
| Free cash flow | $136.66M | $45.99M | $156.80M | $141.78M |
| Cash & equivalents | $158.54M | $128.45M | $205.40M | $120.50M |
| Total assets | $1.26B | $1.45B | $1.32B | $836.65M |
| Total liabilities | $571.81M | $390.93M | $796.00M | $188.85M |
| Shareholders' equity | $693.11M | $1.06B | $522.60M | $647.80M |
| Return on year-end equity | 1.0% | -3.6% | 10.1% | 15.4% |
| Shares outstanding | 41.12M | 57.46M | 52.10M | 105.97M |
Revenue, most recent five fiscal years
| Fiscal year | Pacira BioSciences, Inc. | Supernus Pharmaceuticals, Inc. | Emergent BioSolutions Inc. | Corcept Therapeutics Inc |
|---|---|---|---|---|
| Latest | $726.41M Ended 2025-12-31 | $718.95M Ended 2025-12-31 | $742.90M Ended 2025-12-31 | $761.41M Ended 2025-12-31 |
| 1 year earlier | $700.97M Ended 2024-12-31 | $661.82M Ended 2024-12-31 | $1.04B Ended 2024-12-31 | $675.04M Ended 2024-12-31 |
| 2 years earlier | $674.98M Ended 2023-12-31 | $607.52M Ended 2023-12-31 | $1.05B Ended 2023-12-31 | $482.38M Ended 2023-12-31 |
| 3 years earlier | $666.82M Ended 2022-12-31 | $667.24M Ended 2022-12-31 | $1.12B Ended 2022-12-31 | $401.86M Ended 2022-12-31 |
| 4 years earlier | $541.53M Ended 2021-12-31 | $579.77M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $365.98M Ended 2021-12-31 |